Canaccord Genuity Reiterates a 'Buy' on Anacor Pharmaceuticals (ANAC); Potential From Novel Dermatologic Drug Development Pipeline.
Tweet
Share
E-mailGet Alerts ANAC Hot Sheet
Price: $10.19 --0%
Rating Summary:
7 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
7 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Anacor Pharmaceuticals (NASDAQ: ANAC) price target of $11.00.
Analyst, George Farmer, said, "We reiterate our rating on ANAC shares on potential of the company’s novel dermatologic drug development pipeline...Two fully enrolled pivotal trials mature evaluating lead onychomycosis drug candidate tavaborole, from which data is expected Q4/12 and Q1/13. Per management, subject compliance remains high, with a drop rate way below designed expectations so far."
"Q4/11 cash of $51M plus $20M from a Q1/12 equity financing supports management guidance of at least $25M by year-end. We model for sufficient cash into the two Phase III tavaborole and all AD Phase II read-outs into H2/13."
For an analyst ratings summary and ratings history on Anacor Pharmaceuticals click here. For more ratings news on Anacor Pharmaceuticals click here.
Shares of Anacor Pharmaceuticals closed at $5.59 yesterday.
Analyst, George Farmer, said, "We reiterate our rating on ANAC shares on potential of the company’s novel dermatologic drug development pipeline...Two fully enrolled pivotal trials mature evaluating lead onychomycosis drug candidate tavaborole, from which data is expected Q4/12 and Q1/13. Per management, subject compliance remains high, with a drop rate way below designed expectations so far."
"Q4/11 cash of $51M plus $20M from a Q1/12 equity financing supports management guidance of at least $25M by year-end. We model for sufficient cash into the two Phase III tavaborole and all AD Phase II read-outs into H2/13."
For an analyst ratings summary and ratings history on Anacor Pharmaceuticals click here. For more ratings news on Anacor Pharmaceuticals click here.
Shares of Anacor Pharmaceuticals closed at $5.59 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Revolution (RVMD) PT Raised to $179 at Bernstein SocGen Group
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
